Yann LeCun has joined the advisory board of Cellular Intelligence, a US biotech company using AI to refine how stem cells are turned into neurons. The company is applying that work to STEM-PD, a cell therapy for Parkinson’s disease that it expects to enter phase 2 in 2027.
Yann LeCun Watch analysis
What happened
Cellular Intelligence says it is using AI to analyse the many conditions that can affect cell differentiation, aiming to find more stable ways to produce the desired cells. The company’s programme centres on STEM-PD, which it licensed from Novo Nordisk in May and which has received FDA fast-track designation, according to Chosun Biz.
LeCun, the former Meta chief AI scientist, and biotech entrepreneur Robert Langer joined the company’s advisory board on 21 September, the report says. It also puts Cellular Intelligence’s funding at $62 million.
Why it matters
This is a practical, less familiar use of AI in biology: not simply predicting a drug target, but helping control a sensitive manufacturing process. Small changes in growth-factor exposure can alter the cells produced, Chosun Biz reports. More consistent production could matter to a cell therapy’s development, though the company’s approach and its clinical prospects remain to be demonstrated.
STEM-PD is not an approved treatment. The report says the programme is expected to enter phase 2 in 2027, so the immediate news is about the research and development effort, not a therapy patients can access.
Our read
The interesting question is whether AI can make cell production reliably repeatable, where biology has a habit of treating “same recipe” as a suggestion. LeCun’s role adds a high-profile AI researcher to the effort, but the meaningful test will be evidence that the platform improves the cells or the process in ways that hold up beyond the company’s claims.
What to watch
- Whether STEM-PD enters phase 2 as expected in 2027.
- What Cellular Intelligence publishes about the AI system and its effect on cell production.
- Whether the company reports clinical evidence for STEM-PD as development progresses.
Discussion spark: Should AI-guided cell manufacturing be judged mainly by more consistent production, or only by whether it improves patient outcomes?
Sources and evidence
- Parkinson drug race accelerates as LeCun, SK Biopharm, Roche advance – CHOSUNBIZ – biz.chosun.com (26 September 2026, 21:00 UTC)
Independent WittyWires tracker for public updates about Yann LeCun. Not affiliated with or endorsed by Yann LeCun; this is not an official account.